Allergy Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Allergen Type (Food, Inhaled, Drug, Other Allergen Types), By Test Type (In Vivo Tests, In Vitro Tests) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

What is the Size of Allergy Diagnostics and Therapeutics Market?

The global allergy diagnostics and therapeutics market size was valued at USD 37.03 billion in 2025 and is projected to grow from USD 40.67 billion in 2026 to USD 86.11 billion by 2034, registering a CAGR of 9.83% during the forecast period from 2026 to 2034. North America dominated the allergy diagnostics and therapeutics market with a market share of 37.62% in 2025.

Type Insights

The diagnostics segment is estimated to grow at a CAGR of 10.37% during the forecast period. Growth is supported by increasing adoption of component-resolved diagnostics (CRD), which enables precise identification of individual allergen molecules and improves differentiation between true allergies and cross-reactivity. Expanding use of multiplex microarray testing platforms allows simultaneous detection of multiple allergen sensitivities, improving diagnostic efficiency in specialized allergy laboratories.

The therapeutics segment is projected to register a CAGR of 10.13% in the allergy diagnostics and therapeutics market. The segment is expanding due to the growing adoption of antihistamines, mast cell stabilizers, and immunomodulators. These therapies offer improved symptom control for severe allergic conditions such as asthma and chronic urticaria while reducing reliance on long-term corticosteroid treatments.

Request Customizationto receive a tailored report.

Allergen Type Insights

The inhaled segment dominated the market with a revenue share of 48.50% in 2025 due to increasing use of targeted inhaled corticosteroid–long-acting bronchodilator combination formulations that deliver localized anti-inflammatory action directly to the respiratory tract. The introduction of smart inhaler devices with digital dose tracking and improved particle-delivery technologies is enhancing treatment adherence and therapeutic efficiency in allergic respiratory conditions.

The drug allergen segment is projected to grow at a CAGR of 10.94% during the forecast period due to increasing clinical adoption of in vitro drug hypersensitivity testing, including specific IgE assays and basophil activation tests, which improve detection of allergic reactions to antibiotics and anesthetics. Rising hospital pharmacovigilance programs are encouraging systematic drug allergy screening before prescribing high-risk medications.

Test Type Insights

The in vivo tests segment is projected to grow at a CAGR of 10.42% during the forecast period due to growing clinical dependence on skin prick and intradermal testing for real-time allergen response evaluation, which helps physicians confirm clinically relevant sensitivities. Improved standardized allergen extracts and automated skin testing devices are further enhancing test accuracy, reproducibility, and efficiency in specialized allergy clinics.

The in vitro tests segment is projected to grow at a CAGR of 11.03% during the forecast period, driven by the adoption of high-sensitivity chemiluminescent immunoassay systems that enable precise detection of low-level allergen-specific antibodies. Expanding use of automated laboratory analyzers integrated with laboratory information systems is also improving testing throughput and diagnostic consistency in large clinical laboratories.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America Allergy Diagnostics and Therapeutics Market

North America held a dominating share of the market in 2025 with a share of 37.62% due to the strong presence of specialized allergy treatment infrastructure and clinical research activities. The US has more than 1,200 dedicated allergy clinics providing immunotherapy, treating more than 4.5 million patients annually, which significantly accelerates the adoption of diagnostic tests and targeted therapeutics. Rapid integration of electronic health record–linked allergy decision-support systems in hospitals automatically flag potential drug or environmental allergies during prescribing, prompting confirmatory diagnostic testing and specialist referrals. These factors collectively drive market growth in North America.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Allergy Diagnostics and Therapeutics Market

The Asia Pacific allergy diagnostics and therapeutics market is anticipated to register a CAGR of 11.64% during the forecast period. The market is growing due to the rapid expansion of large-scale national allergy screening programs and hospital network modernization. China’s National Health Commission has launched programs targeting the screening of nearly 50 million school children for allergic diseases, significantly increasing demand for diagnostic assays and follow-up therapies. Cities such as Beijing, Delhi, and Seoul report rising allergy prevalence due to particulate pollution and urban environmental exposure, expanding allergy testing programs and respiratory allergy treatment services.

Europe Allergy Diagnostics and Therapeutics Market

The allergy diagnostics and therapeutics market in Europe is supported by strong immunotherapy manufacturers and standardized allergen production facilities across countries such as Germany, France, and Spain. These facilities manufacture pollen and mite allergen extracts, enabling precise immunotherapy formulations tailored to Europe’s diverse environmental allergen profiles. The implementation of pan-European allergy surveillance and research initiatives, such as multicenter clinical networks that track allergen prevalence and treatment outcomes. Such initiatives further boost market growth in European countries.

Middle East & Africa Allergy Diagnostics and Therapeutics Market

The Middle East & Africa allergy diagnostics and therapeutics market is primarily driven by the development of national allergy registries and structured surveillance programs in countries such as the UAE. The UAE’s National Allergy Registry collects epidemiological and treatment outcome data, enabling standardized diagnostic protocols and improving access to allergy testing. Increasing import and distribution partnerships for advanced allergy biologics and diagnostic platforms further support market growth.

Latin America Allergy Diagnostics and Therapeutics Market

The allergy diagnostics and therapeutics market in Latin America is supported by rapid expansion of allergy testing volumes in Brazil’s private healthcare networks, where approximately 5.1 million allergy diagnostic tests are performed annually, reflecting growing clinical screening for asthma and food allergies. Growing incorporation of allergy testing into occupational health screening programs in industries such as agriculture, food processing, and chemical manufacturing drives the demand for diagnostics and therapeutics.

Competitive Landscape

The allergy diagnostics and therapeutics market is fragmented, with numerous global pharmaceutical companies, diagnostic technology providers, allergen immunotherapy manufacturers, and regional laboratory service providers competing across the value chain. Major companies such as Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, Sanofi, and AbbVie maintain strong positions through advanced diagnostic platforms and biologic therapies. The specialized immunotherapy providers and emerging biotechnology firms focus on allergen vaccines, molecular diagnostics, and precision allergy treatments. Competition is driven by technological innovation and increasing investment in targeted biologics and next-generation immunotherapy solutions.

List of Key and Emerging Players in Allergy Diagnostics and Therapeutics Market